GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Immutep IMM.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.03

+23.81%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Immutep — daily ASX:IMM

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Immutep on TradingView ↗
Market value
A$37.9m
Last close × shares
Volume
38.7m
Shares, 9 Nov 2026

About Immutep

Its shares trade on ASX under the ticker IMM.AX. It has been listed since 23 June 1988. In the fiscal year to 30 June 2026, it reported revenue of A$14.6m and a net loss of A$79.3m. At that date it held total assets of A$83.3m and shareholders' equity of A$61.5m.

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in research, development and commercialization of licensed medical biotechnology. The company is also focused on development of immunotherapeutic products. The firm operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The firm is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.

Figures and description from our data supplier, not checked against the company's own report.

More about Immutep →

Latest on Immutep

Our reporting

We have not reported on Immutep yet.

Next results

25 Feb 2027

Due on 25 Feb 2027. Analysts expect earnings of -0.01 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Immutep's ticker?

Immutep trades as IMM.AX on ASX, under ISIN AU000000IMM6.

What was Immutep's last closing price?

0.03 on 9 Nov 2026. The figure is in AUD and is never converted.

When does Immutep next report results?

Results are expected on 25 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.